Filing Flows › Comparisons › RXRX vs FENC
Recursion Pharmaceuticals vs Fennec Pharmaceuticals: RXRX and FENC compared
Recursion Pharmaceuticals is the larger company: $18.6M of revenue in its latest quarter (Q3 2026) against $17.9M for Fennec Pharmaceuticals (Q2 2026). Recursion Pharmaceuticals is growing faster (+258% against +85% a year earlier). Fennec Pharmaceuticals is more profitable, with an operating margin of 9.7% against -663.9%.
Where the money goes: RXRX and FENC
Recursion Pharmaceuticals (RXRX) · Q3 2026
Recursion Pharmaceuticals, Q3 2026: revenue $18.6M (+258% year over year), operating margin -663.9%, net loss $119M, operating cash flow −$77.4M. The chart follows the revenue to costs, profit and cash.
Fennec Pharmaceuticals (FENC) · Q2 2026
Fennec Pharmaceuticals, Q2 2026: revenue $17.9M (+85% year over year), operating margin 9.7%, net earnings $2.0M, operating cash flow $50K. The chart follows the revenue to costs, profit and cash.
| Recursion Pharmaceuticals (RXRX) | Fennec Pharmaceuticals (FENC) | |
|---|---|---|
| Latest quarter | Q3 2026 | Q2 2026 |
| Revenue | $18.6M | $17.9M |
| Revenue growth, Y/Y | +258% | +85% |
| Operating margin | -663.9% | 9.7% |
| Net earnings | −$119M | $2.0M |
| Net margin | -641.6% | 11.0% |
| Operating cash flow | −$77.4M | $50K |
Where the revenue comes from
Recursion Pharmaceuticals
- Operating revenue: $18.1M (97%)
- Grant revenue: $497K (3%)
Fennec Pharmaceuticals
- PEDMARK product sales, net: $17.2M (96%)
- Other revenue: $710K (4%)
Questions
Which is bigger, Recursion Pharmaceuticals or Fennec Pharmaceuticals?
Recursion Pharmaceuticals is the larger company: $18.6M of revenue in its latest quarter (Q3 2026) against $17.9M for Fennec Pharmaceuticals (Q2 2026).
Is Recursion Pharmaceuticals or Fennec Pharmaceuticals growing faster?
Recursion Pharmaceuticals is growing faster (+258% against +85% a year earlier).
Which is more profitable, Recursion Pharmaceuticals or Fennec Pharmaceuticals?
Fennec Pharmaceuticals is more profitable, with an operating margin of 9.7% against -663.9%.
More: Recursion Pharmaceuticals earnings · how Recursion Pharmaceuticals makes money · Fennec Pharmaceuticals earnings · how Fennec Pharmaceuticals makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Nov 2, 2026; 10-Q filed Aug 13, 2026). Fiscal quarters can end on different dates. Not investment advice.